niacin has been researched along with Coronary Artery Stenosis in 9 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Excerpt | Relevance | Reference |
---|---|---|
"In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, vitamins, simvastatin-niacin plus antioxidants; or placebos." | 9.09 | Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. ( Alaupovic, P; Albers, JJ; Bolson, EL; Brown, BG; Chait, A; Cheung, MC; Dowdy, AA; Fisher, LD; Frohlich, J; Marino, EK; Morse, JS; Zhao, XQ, 2001) |
"Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0." | 6.78 | Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013) |
"We examined the effects of simvastatin-niacin and antioxidant vitamins on changes in high-density lipoprotein (HDL) subpopulations and alterations in coronary artery stenosis, as assessed by angiography." | 5.10 | Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. ( Asztalos, BF; Batista, M; Brown, GB; Cox, CE; Dallal, GE; Horvath, KV; Morse, JS; Schaefer, EJ, 2003) |
"In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, vitamins, simvastatin-niacin plus antioxidants; or placebos." | 5.09 | Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. ( Alaupovic, P; Albers, JJ; Bolson, EL; Brown, BG; Chait, A; Cheung, MC; Dowdy, AA; Fisher, LD; Frohlich, J; Marino, EK; Morse, JS; Zhao, XQ, 2001) |
"Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0." | 2.78 | Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Zambon, A | 2 |
Zhao, XQ | 3 |
Brown, BG | 5 |
Brunzell, JD | 2 |
Kotsia, AP | 1 |
Rangan, BV | 1 |
Christopoulos, G | 1 |
Coleman, A | 1 |
Roesle, M | 1 |
Cipher, D | 1 |
de Lemos, JA | 1 |
McGuire, DK | 1 |
Packer, M | 1 |
Banerjee, S | 1 |
Brilakis, ES | 1 |
Dobiásová, M | 1 |
Frohlich, J | 2 |
Sedová, M | 1 |
Cheung, MC | 2 |
Phan, BA | 1 |
Muñoz, L | 1 |
Shadzi, P | 1 |
Isquith, D | 1 |
Triller, M | 1 |
Asztalos, BF | 1 |
Batista, M | 1 |
Horvath, KV | 1 |
Cox, CE | 1 |
Dallal, GE | 1 |
Morse, JS | 2 |
Brown, GB | 1 |
Schaefer, EJ | 1 |
BISIANI, M | 1 |
FRESIA, P | 1 |
GENOVESE, E | 1 |
MORTARI, A | 1 |
Hokanson, JE | 1 |
Motulsky, AG | 1 |
Chait, A | 1 |
Fisher, LD | 1 |
Dowdy, AA | 1 |
Marino, EK | 1 |
Bolson, EL | 1 |
Alaupovic, P | 1 |
Albers, JJ | 1 |
Freedman, JE | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial[NCT03542110] | Phase 4 | 46 participants (Actual) | Interventional | 2018-08-04 | Terminated (stopped due to Withdrawal of medication and funding support by Sponsor) | ||
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial[NCT01221402] | Phase 2 | 38 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy[NCT00715273] | Phase 4 | 217 participants (Actual) | Interventional | 2001-05-01 | Completed | ||
Heartmatters Challenge - First Responders[NCT03322046] | 185 participants (Actual) | Observational | 2013-10-08 | Completed | |||
High Density Lipoprotein Subspecies and Coronary Disease[NCT00005676] | 2,700 participants (Actual) | Observational | 2000-04-30 | Completed | |||
[NCT00000553] | Phase 3 | 0 participants | Interventional | 1994-09-30 | Completed | ||
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)[NCT00397657] | Phase 4 | 400 participants (Anticipated) | Interventional | 2006-11-30 | Terminated (stopped due to Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.) | ||
HDL Increased Plaque Stabilization in the Elderly[NCT00127218] | Phase 3 | 145 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
Intervention | mm^3/year (Mean) |
---|---|
1 - Single Therapy Group | -4.6 |
2 - Double Therapy Group | -15.1 |
3 - Triple Therapy Group | -9.4 |
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
Intervention | percentage change/year (Mean) | |
---|---|---|
LRNC change | Wall Volume change | |
1 - Single Therapy Group | -1.6 | -0.6 |
2 - Double Therapy Group | -3.6 | -1.4 |
3 - Triple Therapy Group | -2.8 | -1.2 |
Any cardiovascular events such as death from any cause, nonfatal myocardial infarction, stroke, and revascularization procedures (PCI or CABG) due to unstable ischemia will be recorded and verified. (NCT00715273)
Timeframe: Measured at Years 3, 4, and 5
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Composite Measured at Year 3 | Composite Measured at Year 4 (cumulative) | Composite Measured at Year 5 (cumulative) | |
1 - Single Therapy Group | 6 | 7 | 9 |
2 - Double Therapy Group | 6 | 11 | 11 |
3 - Triple Therapy Group | 7 | 9 | 9 |
The primary endpoint is Changes in plaque architecture and composition directly measured by magnetic resonance imaging (MRI) in the aorta and carotid arteries. (NCT00127218)
Timeframe: 18 months
Intervention | percentage of internal carotid artery (Mean) |
---|---|
Niacin Plus Statin | 7 |
Placebo Plus Statin | 5 |
Cerebrovascular events (newly diagnosed) such as Stroke and Myocardial revascularization (specifically coronary artery bypass grafting, percutaneous coronary interventions, carotid endarterectomy) were recorded (NCT00127218)
Timeframe: 18 months
Intervention | Participants (Count of Participants) |
---|---|
Any Statin Plus Niacin | 6 |
Any Statin Plus Placebo | 2 |
6 trials available for niacin and Coronary Artery Stenosis
Article | Year |
---|---|
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.
Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti | 2015 |
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.
Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti | 2015 |
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.
Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti | 2015 |
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.
Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti | 2015 |
Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.
Topics: Antioxidants; Apolipoproteins B; Atherosclerosis; Cholesterol; Coronary Angiography; Coronary Stenos | 2011 |
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment
Topics: Blood Glucose; Carotid Stenosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary | 2013 |
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression; | 2003 |
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression; | 2003 |
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression; | 2003 |
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression; | 2003 |
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
Topics: Adult; Analysis of Variance; Apolipoproteins B; Colestipol; Coronary Angiography; Coronary Stenosis; | 2006 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas | 2001 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas | 2001 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas | 2001 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas | 2001 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas | 2001 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas | 2001 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas | 2001 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas | 2001 |
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas | 2001 |
3 other studies available for niacin and Coronary Artery Stenosis
Article | Year |
---|---|
Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease.
Topics: Bile Acids and Salts; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Stenosis | 2014 |
[Capacity of iproniazid to inhibit in vivo the coronary constrictor effect of pitressin].
Topics: Antidiuretic Hormone Receptor Antagonists; Coronary Stenosis; Coronary Vessels; Humans; IgA Vasculit | 1958 |
Antioxidant versus lipid-altering therapy--some answers, more questions.
Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Coronary Stenosis; Drug Therapy, | 2001 |